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PFOCUS ISSUE: PLAQUE NEOVASCULARIZATION,
HEMORRHAGE, AND VULNERABILITY Viewpoint
Elimination of Neoangiogenesis for Plaque Stabilization
Is There a Role for Local Drug Therapy?
Frank D. Kolodgie, PHD,* Jagat Narula, MD, PHD, FACC,† Chun Yuan, PHD,‡
Allen P. Burke, MD, FACC,* Aloke V. Finn, MD,§ Renu Virmani, MD, FACC*
Gaithersburg, Maryland; Irvine, California; Seattle, Washington; and Boston, Massachusetts
Emerging data suggest that intraplaque hemorrhage is critical in promoting atherosclerotic lesion instability.
Because red blood cell membranes are a rich source of free cholesterol and accumulated red blood cells within
plaques promote inflammation, intraplaque hemorrhage is associated with expansion of the necrotic core.
Plaque hemorrhage results from the development of immature neointimal vasa vasorum. Therefore, it is pro-
posed that molecular therapies designed to eliminate pathologic neovascularization within developing lesions
will interrupt the process of hemorrhage and decrease the rate of necrotic core expansion. The elimination of
intraplaque neovascularization would involve targeting of pre-existing and new vessel development. The concept
of vascular regression has met some success in other neovascular-dependent diseases, including macular de-
generation and malignancies. The efficacy of this novel approach is dependent on gaining critical knowledge of
the environment required to support development and maturation of the vasa vasorum within varying plaque
types. A multitargeted approach involving selective local antiangiogenic agents should contribute to prevention
of plaque progression and its clinical consequences. (J Am Coll Cardiol 2007;49:2093–101) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.083u
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spproximately 75% of acute coronary events and 60% of
ecently symptomatic carotid artery disease are caused by
isruption of an atheromatous plaque (1–3). Although the
nderlying mechanism for conversion of an asymptomatic
broatheroma to a lesion vulnerable to rupture is not
stablished, the significance of intraplaque hemorrhage in
esion stability has recently been proposed as an important
ontributor (4–6). A series of manuscripts in the current
ssue of the Journal propose the association of hypercholes-
erolemia with the development of increased vasa vasorum
round coronary vessels and intraplaque neovascularization.
he newly formed vasculature in the plaque is demonstrated
o be incompetent, because red blood cells (RBCs) con-
tantly leak into the microenvironment, exaggerated partic-
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006, accepted October 30, 2006.larly during intraplaque hemorrhage. The RBC mem-
ranes are rich in free cholesterol, and the extent of RBC
eakage is suggested to be responsible for the rapid expan-
ion of the necrotic core. It is therefore proposed that
limination of the intraplaque neovascularization should
ubstantially decrease the accumulation of RBC-derived
holesterol in plaques, which may slow the development of
he necrotic core and promote plaque stabilization.
laque Volume and Necrotic Core
ize Determine the Plaque Vulnerability
istopathologic features of lesions critical to acute coronary
vents include plaques with markedly attenuated and in-
amed fibrous caps underlined by a relatively large necrotic
ore. Over 80% of plaques associated with acute rupture
emonstrate more than 50% cross-section vascular area
arrowing, with greater than 75% narrowing found in at
east one-half of lesions (7). Not only are ruptured plaques
izable in circumference, they longitudinally span a median
ength of 9 mm, resulting in relatively large plaque volumes.
uch plaques also contain large necrotic cores, which com-
only occupy more than 25% of the plaque area. The
ecrotic core size and plaque volume interact synergistically,
ncreasing the odds of plaque rupture. This association is so
trong that other factors, including inflammation, only
arginally contribute to lesion vulnerability. The increased
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Eliminating Plaque Angiogenesis May 29, 2007:2093–101plaque burden may not consis-
tently produce obstructive disease,
because more often the outward
and expansive vascular remodeling
obviates any compromise in lumi-
nal integrity. The developing ne-
crotic cores accumulate lipids not
only from circulating lipopro-
eins but also from the cholesterol-enriched RBC mem-
ranes deposited upon intraplaque hemorrhage (4,6).
Plaque hemorrhage is a fairly common event in coronary
therosclerosis. In patients dying from plaque rupture,
ntraplaque hemorrhage can be observed in up to 5 other
ites of the coronary tree (6). In patients dying from stable
evere coronary atherosclerosis, plaque hemorrhages are less
requent. The least number of sites of hemorrhage are seen
n patients dying of noncoronary causes or plaque erosion.
his suggests that lesions with hemorrhage may be prone to
isruption if not adequately treated. These hemorrhagic sites
lso show accompanying increase in neointimal vasa vasorum.
ntraplaque Hemorrhages
ontribute to Enlargement of Necrotic Core
strong association of the extent of intraplaque hemor-
hage (identified by glycophorin A staining, a protein
xclusive to the erythrocyte membrane) with increasing
ecrotic core size has been reported in coronary lesions
rone to rupture (4). Whether the relationship of in-
raplaque hemorrhage and lesion instability offered any
linical significance was further explored in case-control
agnetic resonance imaging (MRI) study of 29 patients
ollowed over 18 months. Of these 29 patients, 15 demon-
trated MRI evidence of intraplaque hemorrhage in carotid
laques at baseline; the remaining 15 patients with compa-
ably sized plaques did not reveal intraplaque hemorrhage
5). The percent change in plaque volume (6.8% vs.
0.15%; p  0.009) and lipid-rich necrotic core volume
28.4% vs. 5.2%; p  0.001) was significantly higher in
he hemorrhage group than in the nonhemorrhage plaques.
urther, the patients with intraplaque hemorrhage at base-
ine were more likely to have new plaque hemorrhage (43%
s. 0%; p  0.006). A follow-up study tested whether
laque characteristics studied by MRI were possible predic-
ors of future ipsilateral cerebrovascular events. In that
rospective study design, serial carotid MRI scans were
erformed every 18 months in 154 asymptomatic patients
ho had ultrasonically verified 50% to 79% carotid stenosis
8). During a mean follow-up of 3 years, 12 carotid
erebrovascular events occurred, which correlated with MRI
haracteristics of thin or ruptured fibrous caps (hazard ratio
HR] 17.0; p  0.001), intraplaque hemorrhage (HR 5.2;
 0.005), large hemorrhagic areas (HR for every 10 mm2
ncrease 2.6; p  0.006), large necrotic cores (HR for every
0% increase 1.6; p  0.004), and large plaque dimensions
Abbreviations
and Acronyms
Ang  angiopoietin
RBC  red blood cell
VEGF  vascular endothelial
growth factorHR for every 1-mm increase 1.6; p 0.008). Although not bonfirmatory, these clinical MRI studies suggested that
emorrhage into the carotid atherosclerotic lesion increases
laque volume and necrotic core size, important hallmarks
f plaque vulnerability to rupture.
vidence of RBC-Derived
holesterol Accumulation
xperimental studies of simulated hemorrhage in at least
he skin (9) and brain (10) suggest complete resolution of
he lesion by 7 days to 14 days, depending on the extent of
emorrhage. The increase in erythrophagocytosis by mac-
ophages leads to the eventual development of foam cells
11), which in most tissues outside the coronary vasculature,
ventually disappear with no pathologic consequence. One
xception, however, involves the maxillary sinus, where
ncreased intrasinus pressure due to drainage obstruction
ay affect venous and lymphatic drainage outflow and lead
o venular microhemorrhages; continued arterial flow into
he sinus mucosa further contributes to relatively large
ocalized hemorrhages (12). In that circumstance, the lym-
hatic drainage may be insufficient to completely remove
he lipid components of the RBC, and cholesterol crystals
recipitate. Hemosiderin-laden macrophages and occa-
ional multinucleated foreign-body giant cells surround the
holesterol clefts in maxillary sinus.
In contrast to organs, the removal of the lipid compo-
ents of RBC membranes in atherosclerotic plaques may
arallel that of the maxillary sinus, because phagocytic
learance of dead macrophages in advanced lesions is
nherently defective (13–15). It is presumed that the rapid
nflux of macrophages in response to the hemorrhage itself
ould lead to postapoptotic macrophage necrosis and en-
anced inflammation in atherosclerotic lesions (16). The
umulative effect of a late lesional hemorrhagic event leads
o the generous expansion of the necrotic core, which
ogether with the proinflammatory response of surviving
acrophages promotes further inflammation, plaque insta-
ility, and thrombosis.
As proof of principle, we developed an animal model
imulating intraplaque hemorrhage to assess the role of
BC-derived cholesterol in lesion progression (4). The
irect injection of 25 l to 50 l packed RBCs into
uiescent aortic atherosclerotic plaques produced excessive
acrophage infiltration along with free cholesterol crystals
nd hemosiderin-laden macrophages. In contrast, control
noninjected) lesions showed the characteristics of a re-
ressed lesion with far fewer lesional macrophages and no
ree cholesterol. Neutral lipids identified by oil red O were
lso significantly greater in injected plaques.
The pathologic response to the extravasation of blood
nvolves a cellular reaction in tissues adjacent to where
onocyte/macrophages are strongly drawn to the lesion.
he signals for this perifocal migration of inflammatory
ells are not fully understood, but proteins in the coagulated
lood likely contribute to cellular activation (17,18). Alter-
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May 29, 2007:2093–101 Eliminating Plaque Angiogenesisatively, the migration of macrophages may be promoted by
ultispecific receptors on erythrocyte membranes, which
an bind a wide array of chemokines in the blood, including
onocyte chemotactic peptide 1 (19). Further, lipid oxida-
ion products from senescent RBCs or iron-catalyzed reac-
ions may liberate potent chemoattractants (20). Nonethe-
ess, the influx of macrophages is the main cellular
omponent in response to hemorrhage in tissues, highlight-
ng the importance of inflammation in the eventual resorp-
ion of the lesion.
laque Hemorrhage Is Associated
ith Neointimal Neovascularization
nd Vasa Vasorum Proliferation
major source of micro- and macrohemorrhages within
therosclerotic lesions is a network of immature blood
Figure 1 Neovascularization in Stable and Unstable Coronary P
Unstable atherosclerotic plaques thin-cap fibroatheroma (A to C) and rupture (D t
adventitial and medial layers (B and E) tend to be in contact with surrounding
characterized by a single lining of luminal endothelium (C and F). The main pathol
macrophages (A). In plaque rupture (D), the fibrous cap is disrupted with a superi
perivascular smooth muscle cells (B and E). In contrast, the vasa vasorum close
rupted “leaky” basement membrane. (G to J) Stable plaques, on the other hand,
show fewer vasa vasorum in the intima, media, and adventitia. (K) Bar graph show
within the bars represent the number of lesions examined. Note that unstable thin
microvessels compared with stable plaques. Endothelial markers: Ulex europeaus
smooth muscle cell (SMC) marker: -actin. (A, D, and G) Movat pentachrome stai
necrotic core; Th  thrombus.essels that develop within the intima of a plaque. Most of
eointimal vessels are endothelialized but rarely possess
ural pericytes or smooth muscle cells. The lack of mural
ells and poorly formed endothelial cell junctions likely
ontribute to the leakiness of neovasculature (21,22). Post-
ortem studies confirm that intraplaque hemorrhage and
laque rupture are proportional to an increase in neovascular
ensity (4,23). Vessel density is increased twofold in vul-
erable plaques and fourfold in disrupted plaques compared
ith severely obstructive stable lesions (6). The newly
ormed vessels closer to the media are relatively more mature
ompared with the vessels closer to the lumen (Fig. 1) (22).
n contrast, vasa vasorum close to lumen structurally only
ontain a single endothelial lining and demonstrate diffuse
erivascular expression of von Willebrand factor. These
essels are associated with remnants of RBC (identified by
s
e associated with marked neoangiogenesis. The microvessels close to the
h muscle cells compared with intimal vessels closer to the lumen, which are
ature of the vulnerable plaque is an intact thin fibrous cap heavily infiltrated by
d luminal thrombus. The adventitial vessels in unstable plaques often show
necrotic core are abnormal, consisting mostly of endothelial cells overlying a dis-
gh severely narrowed, contain mostly collagen, proteoglycans, and calcium, and
e mean number of vasa vasorum for stable and unstable plaques. The values
broatheromas (TCFA) and ruptures show significantly greater densities of
and anti-von Willebrand factor (vWF) antibody immunohistochemical staining;
odified from Virmani et al. (6). A  adventitia; I  intima; M  media; NC laque
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Eliminating Plaque Angiogenesis May 29, 2007:2093–101lycophorin A and hemosiderin) and are typically seen in
lose vicinity to the necrotic core. The micro- and macro-
emorrhages deposit variable amounts of RBC-derived free
holesterol (4). In the stable plaques, there is lower density
f leaky microvessels, absence of intraplaque hemorrhage,
maller necrotic cores, and accordingly smaller amount of
ree crystalizable cholesterol (Fig. 1).
laque Neovascularization and Vasa
asorum Proliferation Are Associated
ith Hypercholesterolemia and Inflammation
he vasa vasorum normally penetrate into the vessel wall at
egular intervals and then bifurcate circumferentially around
he vessel. In contrast, in hypercholesterolemia a dense
etwork of vasa vasorum forms within the adventitia (24),
hich is also associated with an extensive growth of neoin-
imal microvessels. Neovascularization correlates with the
xtent of atherosclerosis and is driven, at least partly, by
ntimal hypoxia. On the other hand, the extent of vasa
asorum decreases significantly with lesion regression and
pon antiangiogenic intervention.
Hypercholesterolemia may trigger the up-regulation of
rowth factor receptors on endothelial and smooth muscle
ells, facilitating the development of neointimal angiogen-
sis. Hypercholesterolemia is associated with inflammation,
hich is also an important stimulus for angiogenesis (25);
nterventions for containment of inflammation attenuate
icrovessel formation (26). The reduction in hypercholes-
erolemia and inflammatory state are equally important in
linical studies evaluating the regression of atherosclerosis
27), and reduction in both factors was found to be most
ffective.
eointimal Neovascularization, Immature
essel Leakiness, and Intraplaque Hemorrhage
mmature microvessels in developing atheroma are poorly
upported by pericytes and comprise a potential source of
arge collections of extravasated RBC, contributing to in-
raplaque hemorrhage. The adventitial vasa vasorum dem-
nstrate more complete maturation, and their newer
ranches traverse the medial layer into the deep intima,
here they become more fragile and leaky (28). The
eovascular leakiness in plaques is most probably due to
nherent structural defects within vessels, proteolytic dam-
ge from ongoing inflammation, the release of selective
ignaling molecules capable of disrupting endothelial cell-
o-cell contact, and/or mechanical forces. The inherent
tructural defect is exemplified in experimental murine
umors where defective cellular linings composed of disor-
anized, loosely connected, branched, overlapping, or
prouting endothelial cells have been identified in areas of
emorrhage (29). In atherosclerosis, leaky intraplaque
asa vasorum have been characterized by ultrastructural
isualization of defects between endothelial junctions
22) or the identification of perivascular von Willebrand gactor (vWf) immunoreactivity around vessels (4,21,30) as a
ign of a less intact or leaky endothelium. Factors that
nduce vessel growth also influence leakiness, and the
rincipal regulator of vascular permeability in pathologic
ngiogenesis is VEGF and its related receptors and cofac-
ors. The VEGF signaling pathway involves an interaction
etween growth factor receptors and certin integrins (31).
he VEGF receptors (VEGFR) may play a critical role in
ell-to-cell adhesion and communication through their
irect interaction with cell-to-cell adhesion molecules. In
ndothelial cells, VEGFR2 associates with vascular endo-
helial (VE) cadherin and provides regulation of junctional
ntegrity and represents one of the potential targets for local
herapy.
The integrity of endothelial cell-to-cell junctions and
ascular barrier functions is regulated by a series of adhesion
olecules that make up tight, gap, and adherens junctions
32). These gaps are large enough for the extravasation of
BC and probably result from disruption of some or all of
he junctional proteins. The VEGF blocks gap junctional
ommunication between adjacent endothelial cells by alter-
ng connexin-43 phosphorylation via VEGFR2 and Src
inase activation. The VEGF also disrupts tight junctional
ommunication by altering phosphorylation of zonula oc-
ludens 1 (ZO-1) and occludens (33) through an Src-
ependent pathway (34). Several adherens junction proteins
VE-cadherin, -catenin, -catenin/plakoglobin, and
120-catenin) become tyrosine phosphorylated downstream
f VEGFR2 after VEGF stimulation, leading to the loos-
ning of endothelial cell-to-cell contact in vitro. Other
ignaling pathways initiated by VEGF/VEGFR2, such as
NOS, PLC, or protein kinase C, may also allow vascular
eakage, and their inhibitors block VEGF-induced perme-
bility (34). In addition, a sustained VEGF-induced per-
eability response is mediated by activation of the uroki-
ase plasminogen activator and receptor system (34).
ogether with VEGF, the angiopoietins (Ang) and their
eceptors tyrosine kinase 1 and 2 (Tie-1 and -2) also play a
ey role in the maintenance and control of vascular leakage
35). Whereas Ang-1 via Tie-2 is involved in maintaining
he integrity of the endothelium, Ang-2 suppresses the
ffects of angiopoietin-1, resulting in vessel destabilization.
liminating Angiogenesis for Plaque Stabilization
ased on the principle that RBC leak is the major deter-
inant of plaque vulnerability, the targeted inhibition of
laque angiogenesis may constitute a valuable therapeutic
pproach toward plaque stabilization (36). Although the
reater part of angiogenesis research is historically linked to
ancer biology, emerging evidence suggests that similar
olecules are involved in nonneoplastic disorders, including
hronic inflammatory and ophthalmic diseases (37). Ocular
iseases such as neovascular age-related macular degenera-
ion (choroidal bleeds) are characterized by aberrant angio-
enesis accompanied by catastrophic effects caused by hem-
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May 29, 2007:2093–101 Eliminating Plaque Angiogenesisrrhage and increased vascular permeability. Vitreous levels
f VEGF have been shown in humans to rise simulta-
eously with growth and leakage of new vessels (38,39).
ntimal vasa vasorum within the coronary artery may share
common pathogenesis with diseases such as macular
egeneration, because there is abnormal and haphazard
rowth of microvessels which are leaky and hemorrhagic.
onceptually, the selective targeting of neoangiogenesis
oses a viable approach for the elimination of pre-existing
nd new growth of microvessels, because the selective
emoval of angiogenic stimuli has been shown to cause
essels to regress, as demonstrated in tumors (40) and heart
41), in particular when vessels have only recently been
ssembled and are still immature.
The vast array of angiogenic inducers, including growth
actors, chemokines, angiogenic enzymes, endothelial spe-
ific receptors, and adhesion molecules, presents a wide
ange of potential therapeutic targets for the elimination of
athologic neovascularization. The expanding list of candi-
ate drugs contains agents primarily targeted against endo-
Figure 2 Diagram Illustrating Molecules Critical to Angiogenes
The scheme highlights the ability of growth factors to positively regulate the “angio
coordinated response involving platelet-derived growth factor and receptor (PDGR/
membrane; EC  endothelial cell; FGF  fibroblast growth factor; FGFR  fibroblast g
centa growth factor; RGD  arginine-glycine-aspartic acid; Tie-2  tunica internal endo
lial growth factor receptor.helial growth factors (VEGF and downstream mediators)
nd its receptors (Fig. 2). Endogenous inhibitors of angio-
enesis include cleavage products of matrix components
uch as arresten, canstatin, and tumstatin from collagen IV,
atstatin from collagen VIII, restin from collagen XV, and
ndostatin from collagen XVIII (25). Other compounds
nclude synthetic inhibitors of cell invasion (marimastat,
eovastat, AG-3340), adhesion (Vitaxin), and proliferation
TNP-470, thalidomide, combretastatin A-4) and com-
ounds that interfere with angiogenic growth factors
interferon-alpha, suramin, and analogues) or their recep-
ors (SU6668, SU5416) (42). For a review of potential
nhibitors of angiogenesis tested in experimental plaques
lease see Moulton (43).
Besides lipid lowering, statins possess reported pleotropic
ffects in humans either promoting or inhibiting angiogen-
sis in some chronic diseases. This dual role is complex and
elated to the organ site, cell type, disease process, and
ossibly statin concentration. Randomized control trials for
ardiovascular disease show that statins produce an unex-
d Potential Therapeutic Targets
switch” to stimulate new vessel formation. Vessel stabilization is mediated by a
) and angiopoietin (Ang) 1. Modified from Moulton et al. (43). BM  basement
factor receptor; Ig  immunoglobulin; MMP  matrix metalloproteinase; PIGF  pla-
cell kinase; VEGF  vascular endothelial growth factor; VEGFR  vascular endothe-is an
genic
PDGFR
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Eliminating Plaque Angiogenesis May 29, 2007:2093–101ected benefit for reducing colorectal carcinoma and mela-
oma (44). It has been suggested that statins exert a biphasic
ose-dependent effect on angiogenesis, at low doses induc-
ng angiogenesis and at high doses inhibiting angiogenesis
45). Animal models with combined ischemia and tumors
ndicate that the dose may not be central to the antiangio-
enic effect, because there was augmented blood flow to
ind-limb ischemic tissue with a marked reduction in tumor
rowth (46).
Because neovascularization is the major response to
ypoxia, the mere existence of intraplaque vessels strongly
upports the notion of hypoxic conditions in human ath-
rosclerosis. The reaction to the stress of hypoxia is medi-
ted in large part by the hypoxia-inducible factor 1 (HIF-1),
transcription factor that drives the expression of genes
ontrolling cell survival and governs the formation of new
lood vessels. Hypoxia-inducible factor 1 consists of a
onstitutively expressed subunit HIF-1 and an oxygen-
elated subunit HIF-1 (or its paralogs HIF-2 and -3).
he existence of HIF-1 in human coronary plaques has
een described (47). The regulation of HIF-1 is complex,
ith multiple pathways involving transcription, translation,
ost-translational modification, and interaction with other
ranscription factors involved. Although selective molecules
ritical to HIF-1 signaling have been identified, only a few
xamples of HIF inhibitors that potentially target selective
athways associated with HIF activation have been de-
cribed, among which include echinomycin and synthetic
olyamides, which inhibit HIF-1 DNA binding, and che-
omin, which blocks recruitment of coactivator p300/CBP
48). The potential targeting of HIF-1 for eliminating
laque angiogenesis remains to be explored.
Whether compounds known to be effective in tumors
ould be beneficial for eliminating plaque angiogenesis
epends on shared coordinated pathways in vessel growth
nd maturation in different vascular beds. This is not always
he case: One example highlighting fundamental differences
n vascular growth responses in different tissues involves the
ffect of Ang-1, which stimulates angiogenesis in the skin
ut suppresses vascular growth in the heart (25). On the
ther hand, the identification of organ-specific targets
ould potentially improve the safety and perhaps efficacy of
ngiogenic therapies, because the drugs could be delivered
ith a degree of specificity to target sites based on the
xpression of selective molecules unique to different vascular
eds. In this respect, patients with malignancies currently
reated with antiangiogenic drugs may provide an opportu-
ity to assess whether those agents impact cardiovascular
isease processes, thus expanding the current knowledge
ase of how different organ systems respond to these drugs.
The molecular and cellular elements of the plaque micro-
nvironment that dictate the growth and development of
ew vessels are not well characterized. It is becoming
pparent, however, that intraplaque vasa vasorum exists in
arious stages of vessel maturation, likely driven by extra-
ellular matrix molecules and surrounding cells by the ielease of various cytokines and growth factors. The degree
f vessel maturation may impact the resistance or respon-
iveness to antiangiogenic therapy. For example, inhibitors
f angiogenesis directed against cell proliferation will likely
e ineffective in quiescent endothelial cells. The concept of
elective molecular targeting for the removal of vessels, as
roposed for other organ systems (49), may circumvent
njury to luminal endothelium of large vessels, minimizing
he risk of thrombosis. Therefore, optimized therapy for
liminating plaque angiogenesis will produce desirable ef-
ects on pathologic neovascularization without influencing
ormal quiescent vessels. Molecular mapping studies, such
s that provided by Hiltunen et al. (50), would further
dentify candidate genes/proteins for selective antiangio-
enic therapy targeted against the atherosclerotic plaque. As
asic knowledge increases about the control of angiogenesis
nd its role in plaque development and instability, it may be
ossible in the future to develop specific antiangiogenic
gents that offer a potential therapy for cancer and angio-
enic diseases.
otential Imaging of
eovascularization for Localized Therapy
he development of antiangiogenic drugs for treating non-
ncologic diseases such as atherosclerosis will require im-
roved monitoring of lesion vascularity to adequately assess
reatment benefits. Although contrast-based intravascular
ltrasound technique is being perfected for the assessment
f vasa vasorum in the plaques (51,52), molecular imaging
trategies such as v3 molecular targeting agents (radiola-
eled arginine-glycine-aspartic acid peptides) (53) or direct
maging of intraplaque hemorrhage using MRI (5,8) or
nnexin-A5 (54) may become useful tools for the identifi-
ation of plaque vascularity. A recent study demonstrated
he ability of v3 integrin-targeted paramagnetic nanopar-
icles to deliver the potent antiangiogenic drug fumagillin to
stablished plaques, thus achieving site-specific delivery of
he drug to plaque-associated neovascularization at a frac-
ion of levels used for systemic treatments (55). Further, the
ame strategy using paramagnetic nanoparticles without
rug provides an integrated noninvasive monitoring of
laque microvascular density as a surrogate marker of
therosclerosis. That study highlights the potential of a
ombined method of drug delivery and imaging, which
ould serve as a unique tool for noninvasive characterization,
rug delivery, and monitoring in atherosclerosis.
s There a Role for
ocal Antiangiogenic Therapy?
hether targeted therapy for vascular regression in other
rgan systems can be directly applied to atherosclerosis is
ebatable, because several lines of evidence suggest that
eovascularization differs depending on its location within
he body and the underlying disease process. Moreover,
mportant criteria regarding the target lesion, drug delivery
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May 29, 2007:2093–101 Eliminating Plaque Angiogenesislatform, and timing of therapy must be established before
strategy to treat angiogenesis in plaques can go forward.
he identification of target lesions is a critical issue, because
urrent technologies have yet to achieve the goal of charac-
erizing plaque morphology to the degree necessary to
orrectly identify rupture-prone lesions according to patho-
ogic criteria. Given these limitations, patients who may
enefit from antiangiogenic agents are those who are at high
isk for recurrent cardiac events, because these individuals
ossess plaques whose near-term risk of causing acute
oronary syndromes is high. Further, the majority of thin-
ap fibroatheromas exist in the proximal and middle left
nterior descending artery, particularly at branch points
56), and the somewhat restricted existence of these lesions
s no coincidence, because flow-related shear stress likely
lays a critical role in lesion burden and vulnerability (57).
inally, as shown in earlier experimental studies, angiogenic
nhibitors will likely be more effective in advanced plaques,
here plaque neovascularization is more prevalent (36).
The focal and rather predictable nature of vulnerable
laques raises the issue of whether appropriate measures of
Figure 3 Diagram Illustrating the Potential Pathologic Outcome
Neovascular Regression of Developing Human Corona
(A) In advanced unstable atheroma, intraplaque vasa vasorum leak, allowing red b
membrane-derived cholesterol and associated macrophage infiltration in response
intraplaque microvasculature should reduce plaque burden and necrotic core size
response. The alterations in lesion substrate should favor plaque stabilization withlaque stabilization could involve localized therapy. Local
elivery of antiangiogenic agents has met with recent
linical success in the treatment of age-related macular
egeneration (58). The localized delivery of antiangiogenic
gents may limit potential adverse effects of the drug and
xpand the selection of drugs that given systemically would
e toxic, let alone reduce the amount and cost of the drug.
ne could envision that either stent- or catheter-based
herapy may be an effective means of delivering drugs to
liminate neovascularization in the clinical setting. Indeed,
s shown in a recent feasibility study, stent-based delivery
f antiangiogenic agents, such as with the VEGF-specific
ntibody (bevacizumab), may be a viable treatment op-
ion (59).
The efficacy of the drug will inferentially dictate whether
t needs to be given as a single dose or repeatedly. Conven-
ional wisdom favors a repeated dosing, because VEGF
ntagonists are typically given systemically for long periods
o inhibit tumor angiogenesis (60,61). In the case of plaque
ngiogenesis it may be potentially convenient to obtain
ontrolled-release delivery locally through stents. Moreover,
r
eroma
ells (RBCs) to spill into the surrounding microenvironment. Red blood cell
orrhage contribute to necrotic expansion. (B) Targeted therapy to eliminate
inating RBC membrane-derived cholesterol and secondary macrophage
uction of plaque size. A adventitia; I intima; M media.Afte
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Eliminating Plaque Angiogenesis May 29, 2007:2093–101imilarly to cancer therapy, a combined therapeutic ap-
roach in plaques inhibiting multiple pathways of angio-
enesis will more likely be effective.
onclusions
t is proposed that molecular therapies designed to eliminate
athologic neovascularization within atherosclerotic lesions
ill interrupt the process of intraplaque hemorrhage, a
ritical event leading to plaque instability (Fig. 3). The
emoval of intraplaque vessels should alleviate the risk of
upture by slowing the rate of necrotic core expansion
hrough eliminating the accumulation of RBC-derived
holesterol and associated macrophage response. The selec-
ive elimination of intraplaque neovascularization will likely
nvolve the targeting of pre-existing and new vessel devel-
pment and expansion. Although this treatment strategy is
n its infancy, the concept of vascular regression has met
ome success in other neovascular-dependent diseases, such
s cancer and age-related macular degeneration. The success
f this novel approach is dependent on gaining critical
nowledge of the environment required for supported de-
elopment and maturation of the vasa vasorum within
laques. A multitargeted approach involving selective anti-
ngiogenic agents, along with improved imaging methods
or visualizing plaque neovascularization to monitor treat-
ent effects, will likely be required to prevent plaque
rogression and its clinical consequences.
Atherosclerosis is a systemic disease with multifocal
iscrete vascular lesions; diffuse vascular involvement, how-
ver, is relatively rare. It is therefore obvious that local
herapy would play only a supplemental role to systemic
ntervention. For such a strategy to become successful it
ould be necessary that noninvasive and invasive imaging
trategies are perfected to precisely identify imminently
nstable plaques. This approach will be mandatory, because
e novo institution of statin therapy has a significant lag
ime to become efficacious at the vessel wall level.
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